Asia-Pacific journal of clinical oncology最新文献

{"title":"Real-World Survival Outcomes of Patients With High PD-L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy.","authors":"Junipearl Cheng, Charlotte McKay, Victoria Bray, Po Yee Yip, Annette Tognela, Peey Sei Kok","doi":"10.1111/ajco.14205","DOIUrl":"https://doi.org/10.1111/ajco.14205","url":null,"abstract":"<p><strong>Background: </strong>Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand-1 (PD-L1) ≥ 50% advanced non-small cell lung cancer (NSCLC). We reviewed the real-world outcomes of patients who received pembro-chemo versus pembro only.</p><p><strong>Methods: </strong>This Australian-based retrospective cohort study used data from patients with advanced NSCLC PD-L1 ≥ 50%, diagnosed between January 2016 and July 2021 and had received first-line pembro-chemo or pembro only. Patients with an EGFR/ALK/ROS1 sensitizing mutation were excluded. Cox proportional-hazards model and Kaplan-Meier methods were used to estimate OS and progression-free survival (PFS).</p><p><strong>Results: </strong>Of 111 eligible patients, 25 received pembro-chemo and 86 received pembro only. After a median follow-up of 15.7 months, median (95% CI) OS was not reached in the pembro-chemo group versus 15.6 (9.5-21.7) months in the pembro-only group (HR 0.57, 95% CI 0.28-1.16, p = 0.12). Median PFS was 12.4 (6.5-18.3) versus 9.5 (6.3-12.6) months in pembro-chemo versus pembro-only groups, respectively (HR 0.62, 95% CI 0.32-1.18, p = 0.18). Objective response rate (ORR) was higher in the pembro-chemo group (60% vs. 30.3%). There were more hospitalizations in the pembro-chemo group versus pembro-only group, 28% versus 18.6%, but immune-related adverse events were similar (32% vs. 32.6%).</p><p><strong>Conclusion: </strong>In patients with PD-L1 ≥ 50% advanced NSCLC, addition of chemo to first-line pembro yielded a higher ORR but no additional benefit in PFS or OS, supporting a shared-decision approach. However, higher rates of hospitalizations seen in the pembro-chemo group should warrant caution in use.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14205"},"PeriodicalIF":1.4,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Dawn-Using Teletrials for Early Phase Drug Development: A Practical Guideline.","authors":"G Gaughran, J Zalcberg, M Voskoboynik, M Shackleton","doi":"10.1111/ajco.14202","DOIUrl":"https://doi.org/10.1111/ajco.14202","url":null,"abstract":"<p><strong>Introduction: </strong>Access to early-phase cancer clinical trials is heavily skewed toward urban patients treated at tertiary centers, creating significant inequity for regional/rural (R/R) populations. For early drug development (EDD) trials, travel requirements are a major barrier to R/R participation. Growing public and governmental policy pressure on pharmaceutical stakeholders and trial centers has driven the exploration of innovative solutions to improve access. Among these, the teletrial model, which has been effective in later-phase studies, presents an opportunity to address recruitment challenges in phase 1 trials. This article provides practical guidelines for implementing teletrials in EDD.</p><p><strong>Methods/results: </strong>This review outlines key operational, regulatory, and logistical considerations for phase 1 teletrials, covering site evaluation, ethics and governance, resource allocation, and funding models. Several teletrial frameworks are presented, tailored to the varying capabilities of satellite sites and the complexities of early-phase trials. Lessons learned from successful pilot initiatives are integrated into the recommendations to help guide site conversion and trial design.</p><p><strong>Discussion: </strong>Phase 1 teletrials are a necessary evolution in clinical trial conduct, driven by increasing demands for equitable access to life-saving therapies. Challenges, including resource-intensive set-up, cost management, and oversight requirements, are acknowledged. However, with proper planning and stakeholder collaboration, teletrials offer significant benefits: increased trial recruitment, improved R/R patient access, and reduced geographic disparities. The expansion of teletrials will be crucial for meeting the recruitment challenges posed by biomarker-driven and rare-disease studies while maintaining safety and scientific integrity.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14202"},"PeriodicalIF":1.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Prognosis and Immunological Features in Hepatocellular Carcinoma Based on Non-Apoptotic Regulatory Cell Death Genes.","authors":"Yefeng Yao, Songjie Wu, Yilin Leiyang, Mengying Li","doi":"10.1111/ajco.14204","DOIUrl":"https://doi.org/10.1111/ajco.14204","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most common liver cancer. Exploring non-apoptotic regulated cell death (RCD) offers a strategy to overcome drug resistance. This study investigates a risk model based on non-apoptotic RCD-related genes to predict clinical outcomes and guide immunotherapy.</p><p><strong>Methods: </strong>We identified genes associated with non-apoptotic RCD in HCC through weighted gene co-expression network analysis (WGCNA) and differential analysis. We then employed non-negative matrix factorization (NMF) clustering to categorize HCC into molecular subtypes related to non-apoptotic RCD and identified differentially expressed genes (DEGs) among these subtypes. We developed a prognostic model utilizing Cox regression and LASSO analysis, stratifying patients into specific risk groups and validating the model's prognostic significance. We subsequently analyzed immune functions and tumor mutation burden (TMB). Finally, we identified potential drugs and evaluated drug sensitivity specific to HCC.</p><p><strong>Results: </strong>We identified four non-apoptotic RCD genes and classified patients into three subtypes. We observed significant differences in immune characteristics and prognostic outcomes among these groups. Six DEGs emerged as key indicators for risk assessment, leading to a prognostic model. High-risk patients face poorer survival rates and increased mortality. Independent prognostic analyses confirm that these models can effectively predict patient outcomes. Notably, in high-risk patients, immune-related functions appear suppressed, facilitating tumor immune evasion.</p><p><strong>Conclusion: </strong>We developed a risk model focused on non-apoptotic RCD genes. This model accurately predicts the prognosis for HCC patients. It may also offer new insights for clinical decisions and immunotherapy.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14204"},"PeriodicalIF":1.4,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized T3-4N+ Rectal Cancer Treatment Strategies: Exploring the Efficacy of Preoperative Synchronized Lateral Lymph Node Simultaneous Integrated Boost Radiation Therapy.","authors":"Xinjue Shi, Siyao Zhong, Xianbin Zheng, Xianxiu Nan, Xuan Liu, Qiteng Liu, Jing Yuan, Yuyan Gao","doi":"10.1111/ajco.14199","DOIUrl":"https://doi.org/10.1111/ajco.14199","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to assess the impact of preoperative synchronized lateral lymph node simultaneous integrated boost radiation therapy on the prognosis of T3-4N+ rectal cancer patients.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 35 patients with rectal cancer from Beijing Luhe Hospital affiliated to Capital Medical University from August 1, 2019 to April 30, 2023, including 22 patients with T3-4N+ rectal cancer, all of whom received the above preoperative therapy: planning gross tumor volume (PGTV): 95% PGTV 55 Gy/2.2 Gy/25 times; planning gross tumor volume of node (PGTVnd): 95% PGTVnd 60 Gy/2.4 Gy/25 times; and planning target volume (PTV): 95% PTV 50 Gy/2 Gy/25 times. Total mesorectal excision (TME) was performed 8-12 weeks after the radiotherapy. The primary endpoints were postoperative pathologic complete response (pCR) rate, downstaging rate, and 1-, 2-, and 3-year local regional recurrence-free survival (LRRFS). The secondary endpoints were anal retention rate, 1-, 2-, and 3-year event-free survival (EFS), overall survival (OS) rates, treatment-emergent adverse events (TEAEs), and perioperative complications.</p><p><strong>Results: </strong>All 22 patients completed treatment, with pCR rate of 22.7% (5/22), anal preservation rate of 77.3% (17/22), tumor downstaging (T-downstaging) rate of 95.5% (21/22), and nodal downstaging (N-downstaging) rate of 100% (22/22), and 1-year postoperative LRRFS, EFS, and OS rates of 100%, 80%, and 86%, respectively; 2-year LRRFS, EFS, and OS rates of 90%, 63%, and 75%, respectively; and 3-year LRRFS, EFS, and OS rates of 90%, 63%, and 63%, respectively. Only two cases of Grade 3 adverse events occurred, which were clinically manageable and did not require permanent treatment cessation.</p><p><strong>Conclusion: </strong>This retrospective analysis demonstrated encouraging short-term outcomes, including a 22.7% pCR rate and a 3-year LRRFS of 90%, with manageable toxicity. Nonetheless, these findings should be interpreted with caution due to the limited sample size and absence of a control arm.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14199"},"PeriodicalIF":1.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of Serum Inflammatory Markers Predict Survival After Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.","authors":"Young Sub Lee, Chan Joo Kim, Jin-Hwi Kim, Yong Seok Lee, Songmi Jeong, Sea-Won Lee, Kwangil Yim","doi":"10.1111/ajco.14201","DOIUrl":"https://doi.org/10.1111/ajco.14201","url":null,"abstract":"<p><strong>Aim: </strong>Cervical cancer is caused by persistent infection with the human papillomavirus. This study aimed to investigate whether the changes in serum inflammatory markers between baseline and posttreatment can predict survival in cervical cancer undergoing definitive chemoradiotherapy (CCRT).</p><p><strong>Methods: </strong>Eighty-one Stage IB-IVA cervical cancer patients treated with definitive CCRT, with serum inflammatory markers obtained at diagnosis and after completion of pre-planned therapy, were included. The percent changes of post-/pretreatment levels × 100% were calculated for neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic inflammation response index (SIRI), and systemic immune-inflammation index (SII). The cutoffs were obtained with the maximal chi-square statistics.</p><p><strong>Results: </strong>At a median follow-up of 28 months, the 2-year overall survival (OS) was 75.4%. The 2-year OS for patients with low versus high percent change was as follows: post-/pre-NLR (87.7% vs. 67.8%), post-/pre-MLR (75.9% vs. 71.1%), post-/pre-SIRI (76.5% vs. 61.7%), and post-/pre-SII (91.7% vs. 67.2%) (all p < 0.05). The hazard ratios (HR) in multivariate analysis were as follows: post-/pre-NLR (5.53, 95% confidence interval [CI]: 1.65-18.52), post-/pre-MLR (3.39, 95% CI: 1.39-8.26), post-/pre-SIRI (5.11, 95% CI: 1.92-13.57), and post-/pre-SII (6.57, 95% CI: 1.77-24.36) (all p < 0.05).</p><p><strong>Conclusion: </strong>This study demonstrates the impact of the dynamics of serum inflammatory markers on survival. It has been consistently demonstrated across the markers. To adopt these markers for personalized treatment decisions, a better understanding of their relation with the actual tumor microenvironment is warranted.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14201"},"PeriodicalIF":1.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Impact of Upfront Dose Reduction of the First Cycle of First-Line Treatments on Safety and Survival in Elderly Patients With Non-Small Cell Lung Cancer.","authors":"Takashi Nojiri, Akiisa Omura, Kiyotsugu Iede, Utae Katsushima, Masahiko Higashiyama","doi":"10.1111/ajco.14203","DOIUrl":"https://doi.org/10.1111/ajco.14203","url":null,"abstract":"<p><strong>Background: </strong>The number of elderly patients with non-small cell lung cancer (NSCLC) is rapidly increasing worldwide. Elderly patients with NSCLC are less suited to active treatment than younger patients. Upfront dose reduction (UDR) of the first cycle of first-line treatment is sometimes chosen for elderly patients due to adverse events. We investigated the clinical impact of UDR in elderly NSCLC patients.</p><p><strong>Methods: </strong>From a prospective database of consecutive NSCLC patients without actionable genomic alterations who received first-line treatment between November 2018 and March 2024, we analyzed 131 patients of ≥65 years of age. Patients were treated with standard-dose chemotherapy between November 2018 and December 2021 and UDR chemotherapy between January 2022 and March 2024. We retrospectively compared the incidence of adverse events and clinical outcomes between the standard-dose and UDR groups.</p><p><strong>Results: </strong>The incidence of treatment-related death was relatively lower in the UDR group (UDR vs. standard-dose: 3.0 vs. 13.6%; p = 0.0624). There was no significant difference in the incidence of immune-related adverse events between the two groups. The objective response rate was higher in the UDR group (UDR vs. standard-dose: 61.5 vs. 48.5%; p = 0.161). The log-rank analysis showed that the UDR group had significantly longer median progression-free survival/overall survival relative to the standard-dose group.</p><p><strong>Conclusions: </strong>UDR as a first-line treatment was safe and could be a suitable approach for elderly patients with NSCLC. Further research is needed to evaluate the clinical outcomes in the treatment of elderly NSCLC patients.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":"e14203"},"PeriodicalIF":1.4,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Clinical Variation of Interest in Standard of Care Practice in a Statewide Bench Marking Audit of Brain Tumor Patient Care.","authors":"Hui K Gan, Laura Tam, Janine Scott, Norah Finn, Ella Stuart, Vishal Boolell, Lawrence Cher, Jonathan Clark, Mike Dally, Anthony Dowling, Katharine Drummond, Martin Hunn, Craig MacLeod, Claire Phillips, Simone Reeves, Ayesha Saqib, Morikatsu Wada, Paul Mitchell, Andrew Danks","doi":"10.1111/ajco.14197","DOIUrl":"https://doi.org/10.1111/ajco.14197","url":null,"abstract":"<p><strong>Background: </strong>The Victorian Tumour Summits are an initiative to engage clinicians and consumers in identifying unwarranted variations in cancer care across the state. The Brain Tumour Summit reviewed the epidemiology, treatment, and outcomes of brain tumor patients for this purpose in 2020.</p><p><strong>Methods: </strong>A retrospective analysis of Victorian brain cancer patients diagnosed between 2013 and 2017 was performed using linked Department of Health administrative datasets including the Victorian Cancer Registry; the Victorian Admitted Episodes Dataset; Victorian Radiotherapy Minimum Data Set; Victorian Emergency Minimum Dataset; and Victorian/National Death Index.</p><p><strong>Results: </strong>A total of 2182 brain cancer patients were included, with a median age of 62 years and male predominance (59%). Most were histologically confirmed (90%). The largest group was glioblastoma (64%) followed by lower grade astrocytomas (14%) and oligodendrogliomas (5%). Nearly all surgery was undertaken in tertiary metropolitan sites regardless of patients' region of residence. Most high-grade glioma patients subsequently received radiotherapy. Radiotherapy for all glioma patients was mostly (75%) delivered by local health service providers. Data regarding oral chemotherapy were not available.</p><p><strong>Conclusions: </strong>Victorian patients had comparable outcomes across different regions, which are consistent with the published literature. The Summit identified three key areas of improvement that could improve patient outcomes and experience: identifying causes of variation in length of hospital stay after surgery and reducing length of stay where appropriate; harmonization of time to start radiotherapy across regional and metropolitan centers; and improved access to palliative care planning and utilization.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Outcomes of Stereotactic Body Radiotherapy for Ground Glass Opacity Nodules and Solid Lung Cancer.","authors":"Yasushi Hamamoto, Kenji Makita, Hiromitsu Kanzaki, Kei Nagasaki, Hiroshi Suehisa, Hisayuki Shigematsu, Tsuyoshi Ueno, Daijiro Harada, Takashi Ninomiya, Toshiyuki Kozuki, Motohiro Yamashita","doi":"10.1111/ajco.14194","DOIUrl":"https://doi.org/10.1111/ajco.14194","url":null,"abstract":"<p><strong>Purpose: </strong>Disease control outcomes of ground glass opacity nodules (GGNs) treated with stereotactic body radiotherapy (SBRT) were evaluated with comparing to solid lung cancer.</p><p><strong>Material and methods: </strong>Patients who received SBRT for primary lung cancer with maximum tumor diameter of 5 cm or smaller between July 2006 and February 2012 were retrospectively reviewed.</p><p><strong>Results: </strong>A total of 169 primary lung cancer (GGNs, 40; solid lung cancer, 129) in 151 patients (age, 55-92; median, 79) were treated with SBRT of 48-62.5 Gy in 4-5 fractions (mean 50.3 Gy). Median follow-up time was 52 months (3-180 months). For GGNs and solid lung cancer, 5-year local failure free rates (LFF) were 94% and 74% (p = 0.0223), 5-year regional failure free rates (RFF) were 95% and 79% (p = 0.0293), 5-year distant failure free rates (DFF) were 86% and 77% (p = 0.0803), and 5-year overall survival rates (OS) were 73% and 40% (p < 0.0001). In multivariable analysis, tumor appearance of solid lung cancer was the significant unfavorable factor for LFF, RFF, and OS. When GGNs were classified into two groups according to consolidation to maximum tumor diameter ratio (CTR), 5-year LFF, RFF, and DFF were 100%, 100%, and 93% for GGNs with CTR < 0.5, and 71%, 78%, and 62% for GGNs with CTR ≥ 0.5.</p><p><strong>Conclusions: </strong>LFF and RFF after SBRT were significantly better in GGNs compared to solid lung cancer. However, local, regional, and distant failure were not uncommon in GGNs with CTR ≥ 0.5, as were solid lung cancer. Disease control outcomes of SBRT was favorable in GGNs with CTR < 0.5.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Lutetium-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study).","authors":"Cherie Wei Qi Ng, Wei Ming Chua, Winnie Wing-Chuen Lam, Aaron Kian-Ti Tong, David Chee Eng Ng, Charlene Yu Lin Tang, Wei Ying Tham, Ravindran Kanesvaran, Alvin Seng Cheong Wong, Kae Jack Tay, Kenneth Chen, Sue Ping Thang","doi":"10.1111/ajco.14195","DOIUrl":"https://doi.org/10.1111/ajco.14195","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate cancer is the second most common cancer and the leading cause of cancer-related deaths in men. Patients with metastatic castration-resistant prostate cancer (mCRPC) with diffuse bone metastases have limited treatment options due to severe hematological toxicity risks. This study evaluates the safety and efficacy of [¹⁷⁷Lu]Lu-PSMA radioligand therapy (RLT) in this high-risk group within an Asian population.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 48 mCRPC patients with PSMA-avid diffuse bone metastases treated with [¹⁷⁷Lu]Lu-PSMA-RLT between May 9, 2018 and Jan 10, 2023. Patients received up to 4 to 6 initial therapy cycles, with additional cycles considered for those who responded initially but later progressed. Primary and secondary endpoints included overall survival (OS), PSA progression-free survival (PFS), PSA response, clinical response, and toxicity assessment.</p><p><strong>Results: </strong>Median OS was 9.3 months. Any PSA response was observed in 75% of patients. Notably, 48% achieved a ≥50% PSA reduction, correlating with a longer median OS (11.6 vs. 8.6 months, p = 0.03). Median PSA PFS was 3.2 months, with improved outcomes observed in patients achieving ≥50% PSA reduction (6.0 vs. 1.8 months, p < 0.0001). Pain relief was reported in 43% of patients, with a median pain score reduction of 5 points. The most common adverse effect was hepatotoxicity, with anemia in 27%, neutropenia in 27%, and thrombocytopenia in 21%.</p><p><strong>Conclusion: </strong>[¹⁷⁷Lu]Lu-PSMA-RLT demonstrates clinically meaningful benefits in survival and symptom management with an acceptable safety profile for mCRPC patients with extensive bone metastases. These findings support [¹⁷⁷Lu]Lu-PSMA-RLT as a viable treatment option for this challenging population.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of IGFL2 Gene Expression and Prognostic Value in Bladder Cancer Based On TCGA Database.","authors":"Xierzhati Aizezi, Bahatiguli Silafu, Yuan Ma, Zheng Wang, Jifu Li, Jinxing Huang","doi":"10.1111/ajco.14191","DOIUrl":"https://doi.org/10.1111/ajco.14191","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer is a prevalent malignant tumor of the urinary system, primarily affecting middle-aged and elderly populations.</p><p><strong>Objective: </strong>To delineate the pathogenic significance of IGFL2 dysregulation and assess its clinical utility as a theranostic biomarker.</p><p><strong>Methods: </strong>Data were retrieved from the TCGA database, whereas complementary datasets were acquired via the Gene Expression Profiling Interactive Analysis (GEPIA), the Human Protein Atlas (THPA), and cBioPortal databases. IGFL2 emerged as a prominently dysregulated gene and was screened by differential expression analysis. Kaplan-Meier survival curves and Cox regression model were used to analyze its relationship with patient survival. The degree of immune cell infiltration and its correlation with IGFL2 were evaluated, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were performed. All statistical analyses were performed using R software, and p < 0.05 was set as significant.</p><p><strong>Results: </strong>IGFL2 expression was significantly upregulated in bladder cancer (p < 0.05), with a diagnostic AUC of 0.828 (95% CI: 0.761-0.896), and was correlated with pathological TNM staging, histological grading, and overall survival (OS) outcomes. Patients with high expression of IGFL2 were associated with poorer OS and disease-specific survival (DSS) (p < 0.05). High expression of IGFL2 was an independent prognostic risk factor (HR = 3.049, 95% CI: 1.592-5.840, p < 0.001). IGFL2 may be involved in signaling pathways such as PI3K-Akt and MAPK. IGFL2 expression was positively correlated with the infiltration levels of macrophages, Th1 cells, and NK cells (p < 0.05).</p><p><strong>Conclusion: </strong>IGFL2 is highly expressed in bladder cancer and may be associated with a poor prognosis. IGFL2 may become a potential biomarker and an important therapeutic target for bladder cancer patients.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}